RedHill Biopharma (RDHL) Accumulated Expenses (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Accumulated Expenses for 3 consecutive years, with $2.7 million as the latest value for Q4 2024.

  • Quarterly Accumulated Expenses fell 28.34% to $2.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2024, down 28.34% year-over-year, with the annual reading at $2.7 million for FY2024, 28.34% down from the prior year.
  • Accumulated Expenses for Q4 2024 was $2.7 million at RedHill Biopharma, down from $3.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $16.2 million in Q4 2022, with the low at $2.7 million in Q4 2024.
  • Average Accumulated Expenses over 3 years is $7.5 million, with a median of $3.8 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses crashed 76.71% in 2023, then fell 28.34% in 2024.
  • Over 3 years, Accumulated Expenses stood at $16.2 million in 2022, then plummeted by 76.71% to $3.8 million in 2023, then dropped by 28.34% to $2.7 million in 2024.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $2.7 million, $3.8 million, and $16.2 million for Q4 2024, Q4 2023, and Q4 2022 respectively.